Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of antidiabetic drugs that have shown favorable effects in heart failure (HF) patients, irrespective of the left ventricular ejection fraction (LVEF). Recent studies have demonstrated the beneficial effects of empaglifloz...

Full description

Bibliographic Details
Main Authors: Andrew Xanthopoulos, Nikolaos Katsiadas, Spyridon Skoularigkis, Dimitrios E. Magouliotis, Niki Skopeliti, Sotirios Patsilinakos, Alexandros Briasoulis, Filippos Triposkiadis, John Skoularigis
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Life
Subjects:
sodium glucose cotransporter-2 inhibitors
dapagliflozin
remodeling
diabetes mellitus
heart failure
Online Access:https://www.mdpi.com/2075-1729/13/8/1778

Internet

https://www.mdpi.com/2075-1729/13/8/1778

Similar Items